Drs Harrington and Hernandez discuss the limitations of randomized trials and the upcoming ADAPTABLE trial on aspirin dosing developed under the patient-centered-outcomes research initiative from NIH.

Lariat, stroke intervention in patients on NOACs, health literacy and HF, ASA dosing, fitness and AF, and informed consent during STEMI are discussed by Dr John Mandrola.

Noninvasive techniques allow measurement of central blood pressure, but are clinicians (and payers) ready for it?

Dr John Mandrola discusses the QCOR cancellation, LVADs, gene therapy for heart failure, statins in the elderly, and hand sanitizers.

On first inspection everything seems normal in these echos, but a closer look and a calculator reveal the diagnosis.

Ileana Piña, MD reviews ACC presentations on heart failure readmission rates and their impact on Medicare accountability.

By fall, there may be two new drugs in the lipid-lowering toolbox. Seth Bilazarian quizzes Marc Sabatine about what this means for the lipid landscape and the use of a genetic risk score.

John Mandrola reviews congenital heart disease guidelines, sports and long QT, sleep apnea and AF, divorce and MI, and the Dr Oz scandal.

Drs Goldhaber and Bilazarian discuss the cardiologist's increasing role in treating PE with the advent of NOACs.

Susheel Kodali and Thomas Walther review the data from ACC on TAVR vs surgical valve repair. Is the US catching up with Europe?